Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 7:36:11963.
doi: 10.3389/ti.2023.11963. eCollection 2023.

Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?

Affiliations
Review

Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?

Oriol Bestard et al. Transpl Int. .

Abstract

Utilizing assays that assess specific T-cell-mediated immunity against cytomegalovirus (CMV) holds the potential to enhance personalized strategies aimed at preventing and treating CMV in organ transplantation. This includes improved risk stratification during transplantation compared to relying solely on CMV serostatus, as well as determining the optimal duration of antiviral prophylaxis, deciding on antiviral therapy when asymptomatic replication occurs, and estimating the risk of recurrence. In this review, we initially provide an overlook of the current concepts into the immune control of CMV after transplantation. We then summarize the existent literature on the clinical experience of the use of immune monitoring in organ transplantation, with a particular interest on the outcomes of interventional trials. Current evidence indicates that cell-mediated immune assays are helpful in identifying patients at low risk for replication for whom preventive measures against CMV can be safely withheld. As more data accumulates from these and other clinical scenarios, it is foreseeable that these assays will likely become part of the routine clinical practice in organ transplantation.

Keywords: antiviral prophylaxis; cytomegalovirus management; immune monitoring; innate immunity; preventive strategies.

PubMed Disclaimer

Conflict of interest statement

OB’s research is supported by a research grant network from the RICORS (Redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)- A way to build Europe. MF-R holds a research contract “Miguel Servet” (CP18/00073) from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, also co-funded by the European Union. OB, HK, LC, and OM participate in the HORUS project, which has received funding from HORIZON Europe under the grant agreement No.101057651.

Figures

FIGURE 1
FIGURE 1
Immune responses to cytomegalovirus primary infection.
FIGURE 2
FIGURE 2
Potential uses of CMV-CMI assays in CMV-seropositive patients according to preventive strategy and use of T-cell depleting antibodies.

Similar articles

Cited by

References

    1. Raval AD, Kistler KD, Tang Y, Murata Y, Snydman DR. Epidemiology, Risk Factors, and Outcomes Associated With Cytomegalovirus in Adult Kidney Transplant Recipients: A Systematic Literature Review of Real-World Evidence. Transpl Infect Dis (2021) 23(2):e13483. 10.1111/tid.13483 - DOI - PubMed
    1. Griffiths P, Reeves M. Pathogenesis of Human Cytomegalovirus in the Immunocompromised Host. Nat Rev Microbiol (2021) 19(12):759–73. 10.1038/s41579-021-00582-z - DOI - PMC - PubMed
    1. Zangger N, Oxenius A. T Cell Immunity to Cytomegalovirus Infection. Curr Opin Immunol (2022) 77:102185. 10.1016/j.coi.2022.102185 - DOI - PubMed
    1. Bhugra A, Khodare A, Agarwal R, Pamecha V, Gupta E. Role of Cytomegalovirus Specific Cell-Mediated Immunity in the Monitoring of Cytomegalovirus Infection Among Living Donor Liver Transplantation Adult Recipients: A Single-Center Experience. Transpl Infect Dis (2023) 25(1):e14011. 10.1111/tid.14011 - DOI - PubMed
    1. Kotton CN, Torre-Cisneros J, International CMVSF, Aguado JM, Alain S, Baldanti F, et al. Cytomegalovirus in the Transplant Setting: Where Are We Now and What Happens Next? A Report From the International CMV Symposium 2021. Transpl Infect Dis (2022) 24(6):e13977. 10.1111/tid.13977 - DOI - PMC - PubMed

Substances